JP2017000144A5 - - Google Patents

Download PDF

Info

Publication number
JP2017000144A5
JP2017000144A5 JP2016131637A JP2016131637A JP2017000144A5 JP 2017000144 A5 JP2017000144 A5 JP 2017000144A5 JP 2016131637 A JP2016131637 A JP 2016131637A JP 2016131637 A JP2016131637 A JP 2016131637A JP 2017000144 A5 JP2017000144 A5 JP 2017000144A5
Authority
JP
Japan
Prior art keywords
fusion protein
fvii
seq
linker
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016131637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017000144A (ja
JP6422918B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017000144A publication Critical patent/JP2017000144A/ja
Publication of JP2017000144A5 publication Critical patent/JP2017000144A5/ja
Application granted granted Critical
Publication of JP6422918B2 publication Critical patent/JP6422918B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016131637A 2010-06-04 2016-07-01 第vii因子活性を有する融合タンパク質 Expired - Fee Related JP6422918B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0052719 2010-06-04
KR20100052719 2010-06-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013513120A Division JP6143297B2 (ja) 2010-06-04 2011-06-07 第vii因子活性を有する融合タンパク質

Publications (3)

Publication Number Publication Date
JP2017000144A JP2017000144A (ja) 2017-01-05
JP2017000144A5 true JP2017000144A5 (enExample) 2017-04-27
JP6422918B2 JP6422918B2 (ja) 2018-11-14

Family

ID=45067214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013513120A Expired - Fee Related JP6143297B2 (ja) 2010-06-04 2011-06-07 第vii因子活性を有する融合タンパク質
JP2016131637A Expired - Fee Related JP6422918B2 (ja) 2010-06-04 2016-07-01 第vii因子活性を有する融合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013513120A Expired - Fee Related JP6143297B2 (ja) 2010-06-04 2011-06-07 第vii因子活性を有する融合タンパク質

Country Status (13)

Country Link
US (2) US9644197B2 (enExample)
EP (1) EP2576625B1 (enExample)
JP (2) JP6143297B2 (enExample)
KR (1) KR101331101B1 (enExample)
CN (2) CN107188970A (enExample)
AU (1) AU2011262494B2 (enExample)
BR (1) BR112012030941A2 (enExample)
CA (1) CA2801223C (enExample)
ES (1) ES2676874T3 (enExample)
MX (1) MX348567B (enExample)
RU (1) RU2585231C2 (enExample)
WO (1) WO2011152694A2 (enExample)
ZA (1) ZA201300066B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152694A2 (en) 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
EA024507B1 (ru) * 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014129876A1 (ko) 2013-02-25 2014-08-28 에스케이케미칼주식회사 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법
KR102058864B1 (ko) * 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
IL317968A (en) 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
CA3115766A1 (en) 2018-10-08 2020-04-16 Neutrolis, Inc. Engineering of dnase enzymes for manufacturing and therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN110229237A (zh) * 2019-06-24 2019-09-13 王跃驹 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CN101519449A (zh) 2001-08-30 2009-09-02 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
BR0304660A (pt) 2002-05-01 2005-06-07 Schering Ag Anticorpos direcionados a fator de tecido como anticoagulantes
WO2004020454A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
HUE067285T2 (hu) * 2006-03-24 2024-10-28 Bioverativ Therapeutics Inc PC5 mint IX-es faktor propeptidet feldolgozó enzim
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
JP2011526303A (ja) 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
US9968309B2 (en) * 2009-12-08 2018-05-15 Koninklijke Philips N.V. Method and a correction system for correcting tracer-uptake measurements
WO2011152694A2 (en) 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity

Similar Documents

Publication Publication Date Title
JP2017000144A5 (enExample)
RU2012157301A (ru) Слитый белок, обладающий активностью фактора vii
JP2005120106A5 (enExample)
JP2018537087A5 (enExample)
JP2018138049A5 (enExample)
ES2629099T3 (es) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
AR081459A1 (es) Moleculas de union a seroalbumina
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
JP2020517255A5 (enExample)
JP2017018125A5 (enExample)
JP2016505251A5 (enExample)
EA202190889A1 (ru) Клостридиальные нейротоксины, содержащие экзогенную петлю активации
JP2012095652A5 (enExample)
JP2015212284A5 (enExample)
AR071874A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP2015504052A5 (enExample)
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
JP2014509851A5 (enExample)
JP2015524403A5 (enExample)
JP2012512645A5 (enExample)
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
JP2016537981A5 (enExample)
JP2018537089A5 (enExample)